Future studies focusing on the activity of HDAC inhibitors against non-melanoma cancers with mutant BRAF kinase have the potential to expand the scope of this promising class of anticancer drugs, as well as to enrich our knowledge of the influence of HDACs on Ras-MAPK signaling-mediated survival of cancer cells. This evidence concerns the gene HDAC9 and melanoma.